Ab­b­Vie, J&J con­cede a fail­ure for block­buster Im­bru­vi­ca in their PhI­II shot at pan­cre­at­ic can­cer

Pan­cre­at­ic can­cer has beat­en an­oth­er Phase III ef­fort aimed at im­prov­ing the prospects of pa­tients fight­ing the dis­ease.

Just ahead of the 3-day week­end, Ab­b­Vie $AB­BV and their part­ners at J&J $JNJ an­nounced that the late-stage study of Im­bru­vi­ca com­bined with a pair of chemo drugs could do no bet­ter than the chemo ap­proach alone in im­prov­ing ei­ther pro­gres­sion-free or over­all sur­vival for pan­cre­at­ic can­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.